Clinical Trials Logo
  1. Home
  2. Solid Tumor
  3. NCT02806388
  4. Details
NCT02806388 Clinical Trial

Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project

Solid Tumor Clinical Trial

— IMPACT  

Official title:
Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02806388
Other study ID # ECRU-IMPACT
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 2011
Est. completion date December 31, 2025

Study information
Verified date March 2024
Source National Cancer Centre, Singapore
Contact Daniel SW Tan
Phone +65 6436 8000
Email daniel.tan.s.w@singhealth.com.sg
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study aims to screen tumor molecular profile for better selection of anticancer treatment, in particular, allocation to clinical trials if available.

Description:

Molecular profiling will be performed on archival tumor tissue or freshly collected tumor tissue from re-biopsy. Blood, pleural fluid, FNA, and/or saliva may be collected to study the genetic makeup and also to compare the tumor molecular profile. Personalized therapy will be given based on molecular profile.

Recruitment information / eligibility
Status Recruiting
Enrollment 5500
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - Confirmed histological diagnosis of solid tumor - Suitable for systematic treatment and clinical trials - ECOG (Eastern cooperative oncology group) performance status < 2 - Able to provide tumor tissue for molecular profiling - Able to understand and sign the informed consent form Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
Singapore National Cancer Centre, Singapore Singapore

Sponsors (1)
Lead Sponsor Collaborator
National Cancer Centre, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome
Type Measure Description Time frame Safety issue
Primary The molecular and clinical epidemiology for cancer patients being considered for novel therapeutics 5 years
Secondary The proportion of patients who have actionable alterations and enrol into clinical trials 5 years
Secondary The correlation of molecular profiles with clinical outcomes 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2